Richard M Neve

Title: Richard M Neve: Innovator in Cancer Biomarkers and Therapeutics

Introduction

Richard M Neve is a prominent inventor based in San Mateo, CA. He has made significant contributions to the field of cancer research, particularly in identifying biomarkers and therapeutic targets for epithelial cancers. His work has the potential to improve treatment outcomes for patients suffering from these challenging diseases.

Latest Patents

Richard M Neve holds a patent for the Annexin A9 (ANXA9) biomarker and therapeutic target in epithelial cancer. This patent highlights the amplification of the ANXA9 gene in human chromosomal region 1q21, which indicates a likelihood of both in vivo drug resistance and metastasis. The ANXA9 biomarker serves as a crucial indicator of these aspects of the disease. Furthermore, the patent discusses the use of interfering RNAs (iRNAs), such as siRNA and miRNA, and shRNA adapted to inhibit ANXA9 expression. When formulated in a therapeutic composition and delivered to tumor cells, these iRNAs function to treat epithelial cancer effectively.

Career Highlights

Richard M Neve is affiliated with the University of California, where he continues to advance his research in cancer therapeutics. His innovative work has garnered attention in the scientific community, contributing to the understanding of cancer biology and treatment strategies.

Collaborations

Richard has collaborated with notable colleagues, including Wen-Lin Kuo and Joe W Gray. These partnerships have enriched his research and expanded the impact of his findings in the field of cancer research.

Conclusion

Richard M Neve's contributions to cancer research through his patent on the ANXA9 biomarker and therapeutic target exemplify the importance of innovation in medicine. His work not only enhances our understanding of epithelial cancers but also paves the way for new therapeutic approaches.